You are here:

MS in the media - 3 February 2017

Published on

28 January - 3 February 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Disease modifying drug comparison analysis

A risk-benefit analysis has compared three disease modifying drugs for relapsing MS - Tysabri (natalizumab), Gilenya (fingolimod) and Copaxone (glatiramer acetate). The study attempted to quantify the balance between effectiveness in slowing disease progression and the risks of serious side effects (principally PML).

Source: Neurology Advisor

MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing MS

The long-term effects of disease modifying drugs

A ten year study of people taking disease modifying drugs found that fewer people reached EDSS 6 or changed to secondary progressive MS than would have been expected from previous natural history studies.  This indicates that drugs were slowing down MS activity.  However, people who had shown no evidence of disease activity (NEDA) in the first two years showed similar outcomes to the non-NEDA people in the long-term

Source: Neurology Advisor

MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing MS

Uveitis and MS

A Danish study of previous research trials found that the prevalence of MS in people with uveitis (an inflammation in the eye) and the prevalence of uveitis in people with MS were both higher than in the general population. The quality of the research reviewed was criticised

Source: Speciality Pharma Times

MS Trust link: MS research update

Anxiety and cognition

An Australian study found that people with MS with anxiety were more likely to have cognitive problems, especially poor memory.  The research also found that depression and stress were associated with worse cognition

Source: MS Research Australia

MS Trust link: Cognition and cognitive symptoms

Stem cell therapy five year results

The five year results from the HALT-MS study have been published. The 24 participants had had relapses despite treatment in the 18 months before having the stem cells therapy.  At five years, 69% continued to show no relapses, no progression and new lesions (NEDA). In the three year data, this figure had been 78%.

Source: National Institutes of Health

MS Trust link: Stem cell therapy

Computer based cognitive rehab

A study found that people following a computer based cognitive rehabilitation programme showed more improvement in cognition measures than a control group. The rehab included training for working memory, visuospatial memory and divided attention three times a week for six weeks. The control group watched natural history DVDs.

Source: MS News Today

MS Trust link: StayingSmart - a website for people living with cognitive symptoms

Print this page